A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

What Was Tested

This registered phase 2 trial tested Petrelintide.

It had six arms (groups): one (experimental), one (experimental), one (experimental), Arm 4: Petrelintide-matching Placebo + Enicepatide (experimental) and Arm 5: Petrelintide + Enicepatide-matching Placebo (experimental).

The registry classes the interventions as combination product and drug.

Who Took Part

Enrollment: 486 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female participants with Body Mass Index (BMI) ≥ 30 kg/m² OR BMI ≥ 27 kg/m² to \< 30 kg/m² with at least one weight-related comorbidity. History of at least one self-reported unsuccessful dietary effort to lose body weight.

The full record lists 2 inclusion and 14 exclusion criteria; among the exclusions: history of type 1 or type 2 diabetes; self-reported change in body weight \> 5 kg within 90 days prior to screening; previous or planned obesity treatment with surgery (excluding liposuction, cryolipolysis, or abdominoplasty if performed \> 1 year prior to or during screening).

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

Because people in this Petrelintide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Petrelintide group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received Petrelintide.

Those kept unaware of assignments: participant and investigator.

It started in 2026-09-30 with completion listed for 2027-11-12.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Percentage Change in Body Weight between Arms 1 and 6 (time frame: From Baseline to Week 40).

It also tracked 20 secondary outcomes, for example Percentage Change in Body Weight between Arms 2, 3 and Arm 6, Percentage Change in Body Weight between Arms 1, 2, 3 and Arms 4, 5, Percentage of Participants Achieving Body Weight Loss, Change in Body Weight (kilograms [kg]), Change in Body Mass Index (kilograms per square meter [kg/m²]) and Change in Waist Circumference (centimeter [cm]).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Petrelintide in 486 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Petrelintide compound page, all human trials.